Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
SOUTH SAN FRANCISCO, Calif. , March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that updates on several of its preclinical programs are
View HTML
Toggle Summary Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results
SOUTH SAN FRANCISCO, Calif. , March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and announced 2016 financial
View HTML
Toggle Summary Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
One patient of four (25%) achieved a complete remission No dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular
View HTML
Toggle Summary Mateon Therapeutics to Present at 29th Annual ROTH Conference
Presentation on Wednesday, March 15, 2017 at 7:30 am PT
View HTML
Toggle Summary Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completion Three additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody activity SOUTH SAN FRANCISCO, Calif. , Feb.
View HTML
Toggle Summary Mateon Therapeutics to Present at BIO CEO & Investor Conference on February 13, 2017
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it will present a company overview at the 19 th
View HTML
Toggle Summary Mateon Therapeutics to Present Data on Study OX4218 in Neuroendocrine Tumors at ASCO Gastrointestinal Cancers Symposium
- Data Shows Additional Evidence of CA4P Activity - - Investigator-sponsored Study Initiating, Based on OX4218 Results - SOUTH SAN FRANCISCO, Calif. , Jan. 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs)
View HTML
Toggle Summary Mateon Common Stock to Trade on OTCQX Beginning on December 8, 2016
SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that shares of its common stock will be eligible for
View HTML
Toggle Summary Mateon Announces Presentation of OXi4503 AML Study Data at 58th Annual Meeting of American Society of Hematology
- Completed enrollment in the two lowest dose cohorts, third cohort now in progress - - Patients had on average failed 4 prior therapies - - Across the first two cohorts, 20% of patients achieved a complete remission - SOUTH SAN FRANCISCO, Calif. , Dec.
View HTML
Toggle Summary Mateon Provides Corporate Update and Reports Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for
View HTML